Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P456 | DOI: 10.1530/endoabs.63.P456

ECE2019 Poster Presentations Adrenal and Neuroendocrine Tumours 2 (60 abstracts)

An investigation into the role of parathyroid hormone in the regulation of aldosterone secretion in hypertensive cardiovascular patients

Saba Jannat 1 , Maleeha Akram 1 , Sarwat Jahan 2 , Ali Raza Kazmi 3 , Kiran Afshan 2 , Fahim Tahir 4 , Afzaal Ahmed Naseem 5 , Mazhar Qayyum 1 , Muhammad Rafi 6 & Syed Shakeel Raza Rizvi 1,

1Department of Zoology, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Rawalpindi, Pakistan; 2Department of Animal Sciences, Quaid-e-Azam University, Islamabad, Pakistan; 3Aga Khan Health Center, Rawalpindi, Pakistan; 4Reproductive Physiology, Public Health Laboratories Division, National Institute of Health (NIH), Islamabad, Pakistan; 5University of Lahore, Islamabad Campus, Islamabad, Pakistan; 6Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan; 7Department of Zoology, University of Central Punjab, Rawalpindi, Pakistan.

Hypertension or elevated blood pressure (BP) is quantitatively the most important risk factor for development of cardiovascular diseases (CVDs), whereas aldosterone contributes significantly in the development and severity of hypertension. Interestingly, parathyroid hormone (PTH) stimulates aldosterone synthesis by regulating renin-angiotensin-aldosterone system (RAAS). Conversely, RAAS controls PTH secretion, as angiotensin receptor is expressed by human parathyroid tissues and upon activation directly stimulates PTH secretion. In the present study, an interplay between plasma concentrations of aldosterone and PTH was investigated. Hundred hypertensive CVD patients between the age of 21 and 60 years with and without diabetes were included in the investigation. Hundred age and gender matched healthy subjects served as controls. Plasma concentrations of aldosterone were measured using RIA system. Our results showed that 84 patients had low PTH levels, whereas 16 patients exhibited normal concentrations of PTH. Of the 84 patients with low PTH concentration, 48 had normal aldosterone, 29 had low aldosterone and 7 patients had high aldosterone concentrations whether treated with RAASi, non-RAASi, combination of both or remained untreated. All of the 16 patients having normal PTH concentrations also had normal aldosterone concentrations irrespective of any or no treatment. A positive correlation between aldosterone and PTH concentrations was observed in all groups. Similarly, there was a positive correlation between aldosterone concentrations and BP, and PTH and BP in all groups except for patients having high aldosterone and low PTH concentrations. The majority of hypertensive CVD patients fell in the age group of 51–60 years, were males, married, smokers, diabetics, belonged to middle class socioeconomic status, had a disease duration of 1 to 10 years, had exercise free life style, normal BMI and a positive family history of CVD. In conclusion, the present study demonstrates lower concentrations of PTH and normal concentrations of aldosterone in majority of hypertensive cardiovascular patients.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.